Latest Information Update: 25 Mar 2017
At a glance
- Originator Meda
- Class Small molecules
- Mechanism of Action Cholinergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Apr 2016 No recent reports on development identified - Phase-I for Chronic obstructive pulmonary disease in Sweden (unspecified route)
- 17 Jun 2008 Phase-I clinical trials in Chronic obstructive pulmonary disease in Sweden (unspecified route)